Drugs / 2LPAPI®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04232917 | Oct 2020 → Mar 2027 expected | human papilloma virus infection | Labo'Life | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2LPAPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04232917 ↗ |
| Route | Oral | “taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach” NCT04232917 ↗ |